

2/27/02

PATENT
Customer No. 22,852
Attorney Docket No. 09009.0003-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reexamination of:) 90/006499
U.S. Patent No. 5,962,468) Group Art Unit: To Be Assigned
Issue Date: October 5, 1999) Examiner: To Be Assigned
Reexam Control No.: To Be Assigned)
Inventors: Hong *et al.*)
Issued on Application No.: 09/188,063)
Filed: November 9, 1998)
For: 7-(4-AMINOMETHYL-3-)
METHYLOXYIMINOPYRROLI)
DIN-1-YE)-1-CYCLOPROPYL-6)
FLUORO-4-OXO-1,4-DIHYDRO-)
1,8-NAPHTHYRIDINE-3-)
CARBOXYLIC ACID AND THE)
PROCESS FOR THE)
PREPARATION THEREOF)

Box Reexam
Hon. Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER MPEP § 2218

Pursuant to Manual of Patent Examining Procedure (MPEP) § 2218, the owner of the entire interest in U.S. Patent No. 5,962,468 brings to the attention of the Examiner the documents cited and considered during the original prosecution of the '468 patent, which are listed on the attached PTO-1449. This Information Disclosure Statement complies with 37 C.F.R. § 1.98(a).

Copies of the listed documents are attached. With regard to published Japanese patent application 1-100165, an English language abstract is attached.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

The patent owner respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists, and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.
1300 I Street, N.W.
Washington, D.C. 20005
Telephone: (202) 408-4000
Facsimile: (202) 408-4400

Dated: December 27, 2002

By: Andrew C. Sonu *At. no. 41,225*
Andrew C. Sonu
Reg. No. 33,457
Attorney For Patent Owner/Requestor
LG LIFE SCIENCES, LTD.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

PATENT
Customer No. 22,852
Attorney Docket No. 09009.0003-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

90/006499

In re Reexamination of:)
U.S. Patent No. 5,962,468) Group Art Unit: To Be Assigned
Issue Date: October 5, 1999) Examiner: To Be Assigned
Reexam Control No.: To Be Assigned)
Inventors: Hong *et al.*)
Issued on Application No.: 09/188,063)
Filed: November 9, 1998)
For: 7-(4-AMINOMETHYL-3-)
METHYLOXYIMINOPYRROLI)
DIN-1-YL)-1-CYCLOPROPYL-6-)
FLUORO-4-OXO-1,4-DIHYDRO-)
1,8-NAPHTHYRIDINE-3-)
CARBOXYLIC ACID AND THE)
PROCESS FOR THE)
PREPARATION THEREOF)

Box Reexam
Hon. Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.555

Pursuant to 37 C.F.R. § 1.555, the owner of the entire interest in U.S. Patent No. 5,962,468 brings to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement complies with 37 C.F.R. § 1.98(a).

A copy of every patent or printed publication relied upon or referred to in the request for reexamination is attached, accompanied by an English language translation of all the necessary

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

and pertinent parts of non-English language patents or printed publications under 37 C.F.R. §1.510(b)(3).

The patent owner respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists, and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.
1300 I Street, N.W.
Washington, D.C. 20005
Telephone: (202) 408-4000
Facsimile: (202) 408-4400

Dated: December 27, 2002

By: Andrew C. Sonu Reg. No. 44,225
Andrew C. Sonu
Reg. No. 33,457

Attorney For Patent Owner/Requestor
LG LIFE SCIENCES, LTD.